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population based cohort study in the UK 1995-2015
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ABSTRACT
OBJECTIVE
To estimate the incidence and prevalence of resistant 
hypertension among a UK population treated for 
hypertension from 1995 to 2015.
DESIGN
Cohort study.
SETTING
Electronic health records from the UK Clinical Practice 
Research Datalink in primary care.
PARTICIPANTS
1 317 290 users of antihypertensive drugs with a 
diagnosis of hypertension.
MAIN OUTCOME MEASURES
Resistant hypertension was defined as concurrent 
use of three antihypertensive drugs inclusive of 
a diuretic, uncontrolled hypertension (≥140/90 
mm Hg), and adherence to the prescribed drug 
regimen, or concurrent use of four antihypertensive 
drugs inclusive of a diuretic and adherence to the 
prescribed drug regimen. To determine incidence, the 
numerator was new cases of resistant hypertension 
and the denominator was person years of those 
with treated hypertension and at risk of developing 
resistant hypertension. To determine prevalence, the 
numerator was total number of cases with resistant 
hypertension and the denominator was those with 
treated hypertension. Prevalence and incidence 
were age standardised to the 2015 hypertensive 
population.
RESULTS
The age standardised incidence of resistant 
hypertension increased from 0.93 cases per 100 
person years (95% confidence interval 0.87 to 
1.00) in 1996 to a peak level of 2.07 cases per 100 
person years (2.03 to 2.12) in 2004. Incidence then 
decreased to 0.42 cases per 100 person years (0.40 to 
0.44) in 2015. Age standardised prevalence increased 
from 1.75% (95% confidence interval 1.66% to 
1.83%) in 1995 to a peak of 7.76% (7.70% to 7.83%) 
in 2007. Prevalence then plateaued and subsequently 
declined to 6.46% (6.38% to 6.54%) in 2015. 
Compared with patients aged 65-69 years, those aged 
80 or more years were more likely to have prevalent 
resistant hypertension throughout the study period.
CONCLUSIONS
Prevalent resistant hypertension has plateaued 
and decreased in recent years, consistent with a 
decrease in incidence from 2004 onwards. Despite 
this, resistant hypertension is common in the UK 
hypertensive population. Given the importance 
of hypertension as a modifiable risk factor for 
cardiovascular disease, reducing uncontrolled 
hypertension should remain a population health 
focus.
Introduction
Uncontrolled hypertension is a leading risk factor for 
cardiovascular disease related morbidity and deaths.1 
Hypertension is now so widely prevalent, affecting 
one billion people worldwide and directly responsible 
for more than 10 million deaths per year, that it has 
been declared a global public health crisis by the 
World Health Organization.1 2 Resistant hypertension 
is blood pressure ≥140/90 mm Hg despite treatment 
with optimal doses of three different antihypertensive 
drugs, one of which should be a diuretic.3-5 In instances 
where an individual’s blood pressure is at target levels 
but four or more antihypertensive drugs are required, 
resistant hypertension can also be defined.4 Those 
with resistant hypertension have double the risk of 
cardiovascular events than those without resistant 
hypertension, thus making them an important group 
to study.6
Current evidence from a systematic review and 
meta-analysis of 24 studies estimates the prevalence 
of resistant hypertension to be between 14% and 
16% of all patients with hypertension, equalling 
140-160 million people globally.7 These estimates 
may be biased upwards for two reasons. Firstly, four 
randomised studies were included, which likely 
overestimated prevalence owing to selected patients at 
high cardiovascular risk involved in trials.8 Secondly, 
of the 20 observational studies included, which 
should reflect the real world burden of resistant 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Uncontrolled hypertension is a leading risk factor for morbidity and mortality 
from cardiovascular disease and stroke
Those with resistant hypertension (uncontrolled hypertension while treated 
with three antihypertensives inclusive of a diuretic, or those using four 
antihypertensives) have a higher risk of cardiovascular events than those without 
resistant hypertension
Current estimates for the epidemiological burden of resistant hypertension are 
limited by methodological challenges
WhAT ThIS STudy AddS
Incidence of resistant hypertension in more than 1.3 million UK primary care 
patients with hypertension increased from one case per 100 person years in 
1996 to a peak of two cases per 100 person years in 2004; thereafter, the 
incidence decreased to 0.4 cases per 100 person years in 2015
Prevalence increased from 1.75% in 1995 to a peak of 7.76% in 2007 then 
plateaued and declined to 6.46% in 2015, reflecting an earlier decline in 
incidence
Resistant hypertension is common in the UK. Continued effort is needed to 
reduce the proportion of the population with uncontrolled hypertension given its 
intrinsic role in the development of cardiovascular disease
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hypertension more so than randomised studies, 
few assessed adherence to antihypertensive drugs. 
Non-adherence has been found to be the cause of 
uncontrolled hypertension in as many as 50% of 
patients with supposed resistant hypertension.9-11 
One previous observational study, based on US claims 
data, estimated the incidence of resistant hypertension 
at 1.9%.6 However, this estimate was based on data 
from 2002-06 and requires updating. Additionally, 
assessing the burden of resistant hypertension outside 
settings already studied offers benefits in terms of 
wider generalisability.7 11-13
Thus an up-to-date epidemiological study on the 
burden of resistant hypertension, accounting for 
adherence to antihypertensive drug treatment is 
required. Accordingly, we measured the trends in 
incidence and prevalence of resistant hypertension 
among those with treated hypertension between 1995 
and 2015 in the UK primary care setting.
Methods
Study design and data
We conducted a retrospective cohort study, using the 
Clinical Practice Research Database (CPRD-GOLD); a 
nationally representative repository of deidentified 
electronic health records from primary care in the 
UK. CPRD-GOLD holds data on personal information, 
health related behaviours, test results, diagnoses, and 
prescriptions for more than 11 million people in more 
than 670 practices across the UK since 1987.14 It is 
one of the largest databases of longitudinal medical 
records from primary care globally and has been 
extensively validated.14 15 Data quality are monitored 
by CPRD internal processes.
Population
We identified users of antihypertensive drugs between 
1995 and 2015. In CPRD data, prescriptions issued 
by the general practitioner are automatically recorded 
with a product name and number. We used product 
numbers to identify antihypertensive drugs (see 
supplementary material 1) and categorised these 
into 14 classes: vasodilators, centrally acting agents, 
adrenergic blockers, α blockers, angiotensin converting 
enzyme inhibitors, angiotensin receptor blockers, renin 
inhibitors, thiazide diuretics, loop diuretics, potassium 
sparing diuretics (eg, amiloride), aldosterone 
antagonists (eg, spironolactone), β blockers, calcium 
channel blockers, and other. Preparations of fixed dose 
combinations were split into their constituent active 
ingredients, so that patients were attributed with 
exposure to each different category of drug. Eligibility 
for the study began on the latest of: the patient’s 18th 
birthday, the date a patient’s practice was deemed to 
contribute “up-to-standard” data plus one year, the 
patient’s “current registration” date plus one year, and 
the patients’ earliest date of hypertension diagnosis. 
We required a diagnosis of hypertension (see Read 
codes in supplementary material 2) in addition to drug 
use because this method gives similar estimates for 
treated hypertension to those from the health survey 
for England.16 Eligibility ended on the earliest of the 
date on which the patient died, the date on which 
the patient transferred out of practice, the last data 
collection date from practice, and the study end date 
(31 December 2015).
Case definition
Clinical guidelines define resistant hypertension in 
two ways: uncontrolled hypertension (≥140/90 mm 
Hg) during treatment with and adherence to three 
concurrent antihypertensive drugs, inclusive of a 
diuretic, and treatment with and adherence to four 
antihypertensive drugs used concurrently.3-5
To identify patients who met the three drug definition 
we used a multistep process. Firstly, we found users 
of one antihypertensive drug and followed forward to 
assess whether they were prescribed a second drug 
and a third drug within different drug categories. To 
ensure that patients with hypertension were using 
three different drugs concurrently, as opposed to 
switching drugs, we required that patients starting a 
third antihypertensive drug had repeat prescriptions 
for all three drugs within six months of initiating the 
third.
Secondly, in patients who had evidence of concurrent 
treatment with three antihypertensive drugs, inclusive 
of a diuretic, we required a blood pressure reading 
of systolic blood pressure ≥140 mm Hg or diastolic 
blood pressure ≥90 mm Hg within 12 months of 
starting the third drug.3-5 Patients with blood pressure 
readings <140/90 mm Hg did not meet the criteria for 
resistant hypertension and were excluded from our 
case definition at this point but could be considered 
at a future date if new drug changes occurred. The 
index date—the date on which resistant hypertension 
could be identified—was confirmed as the later date of 
evidence of concurrent use of three drugs or the date of 
high blood pressure reading.
Thirdly, we required patients to show good 
adherence to their antihypertensive drug regimen. In 
the absence of dispensing records, which are typically 
used to measure adherence at the population level, we 
instead used prescribing records to estimate a proxy 
for drug adherence. Going backwards one year from 
the index date, we measured proxy adherence from the 
date of the first prescription within this one year period 
until the index date or until the discontinuation date 
of that drug, if before the index date. Discontinuation 
was defined as a gap of 90 or more days between the 
expected finishing date of a prescription and the end 
of the adherence observation period (ie, the index 
date). Using prescription dates and computed days’ 
supply prescribed, we calculated proxy adherence 
as the number of days covered by the drug divided 
by the number of days in the observation period. We 
accounted for leftover days’ supply from previous 
prescriptions by adding to the next supply. Once proxy 
adherence was measured for all antihypertensive 
drugs, we calculated an average across all drugs for 
each patient.17 Binary adherence was defined as an 
average proxy adherence of 80% or more.18 If patients 
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did not meet our definition for proxy adherence, they 
were excluded from the case definition of resistant 
hypertension. We classified patients as meeting the 
case definition of resistant hypertension at the earliest 
opportunity, regardless of whether or not the patient 
went on to be a concurrent user of four drugs.
Patients prescribed four different antihypertensive 
agents, inclusive of a diuretic, were included in the 
case definition in a similar process. First, we required 
patients starting a fourth antihypertensive drug to 
have repeat prescriptions for all four drugs within six 
months of initiating the fourth drug. We did not require 
a blood pressure reading for those taking four drugs 
in concordance with accepted definitions of resistant 
hypertension.4 We assessed adherence in the same 
way as described previously. The index date was the 
earliest date within the six month period that there was 
evidence of concurrent use of four drugs.
Analysis of incidence and prevalence
We calculated annual incidence by dividing the 
number of new cases of resistant hypertension in each 
study year by the number of person years contributed 
by patients with treated hypertension at risk of 
developing resistant hypertension in that year. The 
denominator included patients who were excluded 
from the case definition on the basis of having poor 
adherence. We calculated annual prevalence by 
dividing the number of all live patients with resistant 
hypertension at the end of each year by the number 
with treated hypertension who remained eligible at the 
end of that year.
We calculated crude annual rates of incidence 
and prevalence per 100 person years or 100 people, 
with 95% confidence intervals. To account for a 
changing age structure over time, we used direct 
standardisation by applying age specific rates in 
each year to the standard population, which was 
the 2015 hypertensive population in CPRD. We used 
Poisson models with interaction terms between 
calendar year and sex and between calendar year 
and age category to assess whether the effect of 
sex or age on incidence and prevalence varied over 
time (Wald P values for model). Within a data driven 
approach, we used Joinpoint models to analyse age 
standardised trends over time.19 These models select 
an appropriate number of “turns” in trend data and 
give corresponding slopes to each segment in the 
trend. The optimal number of turns is selected by 
comparing permutation test results between multiple 
Joinpoint models.
Sensitivity analyses
We carried out three sensitivity analyses. The first was 
to assess the influence of defining proxy adherence at 
70%, and not accounting for adherence. The second 
assessed how the three drug definition and the four 
drug definition of resistant hypertension impacted on 
trends. Thirdly, to accommodate that different blood 
pressure thresholds have been used in the management 
of hypertension over time, and for different subgroups, 
we ran an analysis between 1995 and 2000 where we 
defined uncontrolled hypertension as blood pressure 
≥160/90 mm Hg20 and ran an analysis for those aged 
80 or more years where we defined uncontrolled 
hypertension as blood pressure ≥150/90 mm Hg.3 
All analyses were carried out using Stata MP Version 
14.2 and Joinpoint Regression Programme Version 
4.4.0.0.19 21
Patient involvement
No patients were involved in setting the research 
question, nor were they involved in developing plans 
for recruitment, design, or implementation of the study. 
No patients were asked to advise on interpretation or 
writing up of results. There are no plans to disseminate 
the results of the research to study participants.
Results
Study population
More than 1.3 million patients met our inclusion 
criteria for the study (fig 1). Of the total CPRD 
population, 16.46% (95% confidence interval 15.96% 
to 16.96%) were treated for hypertension. Background 
hypertension closely aligned with national estimates 
for treated hypertension over time from health survey 
for England data (see supplementary material 3).
Incidence 
During the study period, 90 973 new cases of resistant 
hypertension occurred in the hypertensive population 
(average non-weighted incidence 1.20 per 100 person 
years, 95% confidence interval 0.77 to 1.79).
Temporal trend—incidence of resistant 
hypertension increased from 0.93 (0.87 to 1.00) per 
100 person years in 1996 to 2.01 cases (1.96 to 2.07) 
in 2001 (annual percentage change 21.49%, 95% 
confidence interval 13.13% to 30.48%, table 1 and 
supplementary material 4). Incidence peaked at 2.07 
cases (95% confidence interval 2.03 to 2.12) per 100 
person years in 2004 (table 1 and supplementary 
material 4). Incidence then declined between 2004 
and 2009 (annual percentage change −17.61%, 
−21.15% to −13.09%) and less rapidly between 2009 
and 2015 (−10.19%, −13.62% to −6.64%) to reach 
0.42 cases (95% confidence interval 0.40 to 0.44) 
per 100 person years (table 1 and supplementary 
material 4).
Age and sex
Those aged more than 70 years were more likely than 
those aged 65-69 years to develop incident resistant 
hypertension during the study period: incidence rate 
ratios 1.12 (95% confidence interval 1.09 to 1.14) for 
those aged 70-74 years, 1.19 (1.16 to 1.23) for those 
aged 75-79 years, and 1.07 (1.04 to 1.10) for those 
aged 80 or more years (see supplementary material 5). 
Women were 2% less likely to develop incident 
resistant hypertension than men (0.98, 0.96 to 0.99, 
see supplementary material 5).
We found no evidence showing that the effect of sex 
or age on incidence varied over time (fig 2).
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Prevalence
Temporal trend—there was an increase from 1.75 
prevalent cases (95% confidence interval 1.66 to 1.83) 
per 100 people in 1995 to 6.46 cases (6.38 to 6.54) 
per 100 people with hypertension in 2015 (table 1). 
This increase was not linear. Between 1995 and 2003 
the annual percentage change was 16.30% (95% 
confidence interval 14.98% to 17.64%, P<0.001). 
This changed to 8.15% (4.06% to 12.40%, P<0.001) 
between 2003 and 2006, peaking at 7.76 cases (95% 
confidence interval 7.70 to 7.83) in 2007 before a brief 
plateau occurred. Thereafter, prevalence decreased 
to 6.46 cases in 2015, with an annual percentage 
change of −3.08% (95% confidence interval −3.93% 
to −2.22%, P<0.001) (see supplementary material 4).
Age and sex—older people were more likely to be 
prevalent cases. The prevalence in those aged 80 or 
more years was 1.43 times (95% confidence interval 
1.39 to 1.46) that of those aged 65-69 years (see 
supplementary material 5). Over time, people aged 
80 or more years were more likely to have prevalent 
resistant hypertension with each passing year from the 
early 2000s onwards (P<0.001) (fig 3). We found no 
evidence showing that the effect of sex on prevalence 
varied over time (fig 3).
Sensitivity analyses
When proxy adherence was defined at a 70% 
threshold, or not accounted for, trends mirrored those 
defined at an 80% threshold, albeit with higher peak 
incidences in 2004 and peak prevalences in 2007, 
respectively (see supplementary material 6). Trends 
in incidence and prevalence were driven by the three 
drug definition, although the prevalence of four drug 
use has increased over time (see supplementary 
material 7). When hypertension was defined using 
a ≥160/90 mm Hg threshold in the 1990s, we found 
similar trends to the main analysis but at lower 
absolute levels (see supplementary material 8). 
When hypertension was defined as ≥150/90 mm 
Hg for those aged 80 years or more, prevalence still 
increased over time, although not as dramatically as 
when hypertension was defined as ≥140/90 mm Hg 
(see supplementary material 8).
discussion
In this longitudinal cohort study of more than 1.3 
million people treated for hypertension, the incidence 
of resistant hypertension increased steeply between 
the late 1990s and the mid-2000s, and peaked at 
Table 1 | Incidence and prevalence of resistant hypertension, 1995-2016
Year
No of incident 
resistant  
hypertension  
cases
Person  
years
Crude incidence  
per 100 person  
years (95% CI)
Standardised* 
incidence per 100 
person years to 2015 
population
No of  prevalent 
 resistant 
 hypertension  
cases
No of prevalent 
 hypertensive  
patients
Crude prevalence  
per 100 people  
(95% CI)
Standardised* 
prevalence to 2015 
population
1995 1657 90 885 1.82 (0.95 to 2.70) 1.75 (1.66 to 1.83)
1996 944 97 842.4 0.96 (0.35 to 1.58) 0.93 (0.87 to 1.00) 2476 10 2534 2.41 (1.46 to 3.37) 2.31 (2.22 to 2.40)
1997 912 114 684.9 0.79 (0.28 to 1.31) 0.78 (0.72 to 0.83) 3217 122 552 2.63 (1.72 to 3.53) 2.52 (2.43 to 2.60)
1998 1250 137 338.3 0.91 (0.41 to 1.41) 0.88 (0.83 to 0.93) 4236 147 899 2.86 (2.00 to 3.73) 2.74 (2.66 to 2.82)
1999 2152 1 649 24.6 1.30 (0.75 to 1.86) 1.26 (1.20 to 1.31) 6077 180 905 3.36 (2.51 to 4.20) 3.21 (3.13 to 3.29)
2000 3836 211 231.4 1.81 (1.24 to 2.39) 1.75 (1.70 to 1.81) 9424 238 657 3.95 (3.15 to 4.75) 3.79 (3.71 to 3.86)
2001 5755 276 205.0 2.08 (1.54 to 2.62) 2.01 (1.96 to 2.07) 14 475 303 426 4.77 (3.99 to 5.55) 4.58 (4.50 to 4.65)
2002 6808 328 707.7 2.07 (1.58 to 2.56) 2.00 (1.96 to 2.05) 20 158 362 534 5.56 (4.79 to 6.33) 5.34 (5.26 to 5.41)
2003 8266 392 679.0 2.10 (1.65 to 2.56) 2.04 (2.00 to 2.09) 26 975 433 536 6.22 (5.48 to 6.96) 5.97 (5.90 to 6.04)
2004 9706 453 736.8 2.14 (1.71 to 2.56) 2.07 (2.03 to 2.12) 34 779 502 592 6.92 (6.19 to 7.65) 6.63 (6.56 to 6.70)
2005 9046 507 018.8 1.78 (1.41 to 2.15) 1.73 (1.70 to 1.77) 41 517 555 801 7.47 (6.75 to 8.19) 7.15 (7.08 to 7.22)
2006 7684 532 992.9 1.44 (1.12 to 1.76) 1.39 (1.36 to 1.43) 45 993 579 957 7.93 (7.21 to 8.66) 7.56 (7.49 to 7.63)
2007 6638 548 982.9 1.21 (0.92 to 1.50) 1.17 (1.14 to 1.20) 48 720 594 430 8.20 (7.47 to 8.92) 7.76 (7.70 to 7.83)
2008 5424 562 479.1 0.96 (0.71 to 1.22) 0.94 (0.91 to 0.96) 50 074 613 436 8.16 (7.45 to 8.88) 7.70 (7.63 to 7.76)
2009 4630 572 852.2 0.81 (0.57 to 1.04) 0.79 (0.76 to 0.81) 50 093 618 126 8.10 (7.39 to 8.81) 7.61 (7.54 to 7.67)
2010 4253 572 209.5 0.74 (0.52 to 0.96) 0.72 (0.70 to 0.74) 49 080 612 663 8.01 (7.30 to 8.72) 7.49 (7.42 to 7.55)
2011 3656 562 208.6 0.65 (0.44 to 0.86) 0.63 (0.61 to 0.65) 47 624 601 090 7.92 (7.21 to 8.63) 7.36 (7.29 to 7.42)
2012 3245 557 515.6 0.58 (0.38 to 0.78) 0.56 (0.54 to 0.58) 45 680 589 656 7.75 (7.04 to 8.46) 7.15 (7.08 to 7.21)
2013 2752 525 711.3 0.52 (0.33 to 0.72) 0.51 (0.49 to 0.53) 41 409 543 900 7.61 (6.88 to 8.35) 6.98 (6.92 to 7.05)
2014 2243 476 279.0 0.47 (0.27 to 0.66) 0.46 (0.44 to 0.48) 34 678 477 887 7.26 (6.49 to 8.02) 6.62 (6.55 to 6.69)
2015 1773 406 033.6 0.43 (0.23 to 0.63) 0.42 (0.40 to 0.44) 26 877 379 686 7.08 (6.23 to 7.93) 6.46 (6.38 to 6.54)
*Standardised to age distribution of 2015 hypertensive population.
People using four drugs
inclusive of diuretic (n=21 897)
People with uncontrolled hypertension using
three drugs inclusive of diuretic (n=154 584)
Adherent users (n=10 274)Adherent users (n=82 537)
Antihypertensive drug users, 1995-2015 (n=2 237 715)
Antihypertensive drug users with diagnosis of hypertension (n=1 317 290)
Users of ≥ 3 concurrent antihypertensive drugs, inclusive of diuretic (n=217 160)
People with resistant hypertension (n=92 811)
Excluded (n=920 425):
  No diagnosis of hypertension (n=885 094)
  Not eligible (n=35 331)
Fig 1 | Flowchart of cohort identification
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approximately two cases per 100 person years in 
2004. Thereafter, the incidence decreased to 0.4 cases 
per 100 person years in 2015. Prevalence increased 
steadily from 1.8% in 1995, peaking at 7.8% in 2007. 
Thereafter, the trend declined gently, reaching 6.5% 
in 2015. Some evidence showed that those aged 80 
or more years were more likely than those aged 65-69 
years to have prevalent resistant hypertension over the 
study period.
Strengths and weaknesses of this study
This is the largest longitudinal study to assess the 
prevalence and incidence of resistant hypertension 
to date. We included more than 1.3 million users 
of antihypertensive drugs with a diagnosis of 
hypertension. This definition ensured the use of 
antihypertensive drugs in those with hypertension, 
although not all blood pressure lowering drugs may 
have been intended for the treatment of hypertension. 
None the less, the prevalence of treated hypertension 
in our study closely matched national prevalence 
estimates for treated hypertension in the health 
survey for England (see supplementary material 
3). In the absence of dispensing data, we used 
prescribing data within CPRD to estimate a proxy 
measure of adherence. Compared with dispensing 
data, prescribing data can overestimate adherence 
to cardiovascular drugs, from 5%22 to 20%.23 This 
may have impacted our results by overestimating 
the number of patients who were adherent, thus 
inflating prevalence and incidence. Assuming a 
worst case scenario whereby our figures represent an 
overestimation of 20%, peak prevalence would then 
be approximately 6% and peak incidence would be 
approximately 1.7 cases per 100 person years. Thus we 
acknowledge the limitations of our method but believe 
our estimates are strengthened by using what was 
the only available approach for assessing adherence 
in our population level data source. Furthermore, 
our various sensitivity analyses on adherence give a 
range of estimates to inform interpretation. We used 
clinic blood pressure measurements in this study, 
which are susceptible to white coat hypertension. 
However, we believe the trends we have reported are 
reflective of real world patterns, based on treatment 
decisions and management pathways as they occur in 
reality in patients with established hypertension. We 
used one blood pressure measurement to ascertain 
whether patients had controlled or uncontrolled 
hypertension. Previous research found that blood 
pressure measurements in electronic health records 
are representative of adjacent measurements24 and 
that using two measurements confers no advantage 
over one measurement in identifying patients with 
resistant hypertension.25 Another source of pseudo-
resistant hypertension is secondary causes; we found 
these to be negligibly distributed among those with 
resistant hypertension (see supplementary material 9).
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We used a general threshold of blood pressure 
≥140/90 mm Hg to define hypertension at the 
population level, which is the accepted threshold 
in national and international guidelines.3 5 26 This 
approach was pragmatic given changing threshold 
values for the general population and for clinical 
subgroups during the study period.3 5 20 26-28 We 
tested the appropriateness of this approach with 
two sensitivity analyses, using a ≥160/90 mm Hg 
threshold for defining hypertension between 1995 and 
2000 and a ≥150/90 mm Hg threshold for defining 
hypertension for those aged 80 or more years, both 
of which indicated broadly similar trends to the 
main analysis. We did not require “optimal” doses 
of each antihypertensive drug because this feature 
of prescribing is highly individualised, especially in 
patients who use polypharmacy. Rather, we focused on 
establishing population trends using population level 
data.
Relation to other studies and key differences
One previous study, using three cross sections 
of the American National Health and Nutritional 
Examination Survey examined prevalence of resistant 
hypertension over time.29 This study reported a linear 
increase in the prevalence of resistant hypertension 
among all patients with hypertension (treated and 
untreated), ranging from 5.5% in 1988-94 to 8.5% in 
1999-2004 to 11.8% in 2005-08. This steady incline in 
prevalence mirrors the incline we noted during similar 
timeframes, although we observed a peak prevalence 
of almost 8% in 2007 and a plateau and decline 
thereafter. Our estimates are likely lower because 
we accounted for adherence in our case definition, 
whereas this was not possible in the American study. 
The same reason is plausibly responsible for the 
difference between a summary prevalence estimate 
of 14% based on 20 observational studies in a recent 
systematic review and our peak prevalence estimate 
of 8%.7 Many of the studies included in the review 
did not account for adherence. In our sensitivity 
analysis, which did not account for adherence, we 
found a prevalence of approximately 14% in the past 
10 years (see supplementary material 6), thus agreeing 
with the results reported in the systematic review and 
recent similar additions to the literature from Africa11 
and Germany.12 By contrast, our results for prevalent 
resistant hypertension (accommodating for adherence) 
agree well with prevalence estimates from the 2011 
health survey for England.30
We found some evidence showing that those aged 
80 or more years were more likely to have prevalent 
resistant hypertension over the study period compared 
with those aged 65-69 years, a finding that was 
robust to sensitivity analyses. This adds to evidence 
from Sweden in which older patients had a higher 
prevalence of resistant hypertension than their 
younger counterparts according to various definitions 
of resistant hypertension.13
Data from the Anglo Scandinavian Cardiac 
Outcomes Trial (ASCOT) estimated incidence of 
resistant hypertension at approximately 34%, 
which is a probable overestimate owing to non-
representativeness of the clinical trial population.31 
In contrast with ASCOT data, an observational study 
found an incidence of approximately 2% based on 
American administrative claims data between 2002 
and 2006, which is more similar to the peak incidence 
of just over two cases per 100 person years we found 
in 2004.6
Meaning of findings and possible mechanisms
The explanation for the trends we found is likely 
multifactorial, relating to detection, treatment, and 
patient awareness of hypertension as opposed to 
changing pathology. The steep increase in incidence 
between 1996 and 2004 might be explained by 
increased detection and treatment of hypertension 
during this period, resulting from a burgeoning 
interest in this clinical area and the publication 
of several seminal clinical trials.32-36 Increasingly 
aggressive treatment was supported by evidence from 
the Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT) that most 
patients needed at least two antihypertensive drugs to 
achieve target blood pressure levels.37 The initiation of 
the Quality and Outcomes Framework in the UK may 
partially explain the fall-off in incidence after 2004. 
This pay for performance scheme incentivised general 
practitioners to more closely monitor blood pressure 
levels and to increase the percentage of patients with 
controlled (<150/90 mm Hg) hypertension. A report on 
the impact of the framework using QRESEARCH data 
from primary care found that rates of blood pressure 
control (<150/90 mm Hg) increased by 65% between 
2001 and 2006.38 Control rates defined as blood 
pressure <140/90 mm Hg increased from 5.7% in 2003 
to 9.9% in 2014.39 Throughout the study period, the 
proportion of patients aware of their hypertension, 
and possibly the importance of its treatment, also 
increased,30 perhaps also playing a contributory role 
in improved control rates.
Conclusions and implications for clinicians and 
policy makers
Resistant hypertension is common in the UK 
hypertensive population. Given the importance 
of hypertension as a modifiable risk factor for 
cardiovascular disease,40 continued efforts 
are warranted to reduce the proportion of the 
population with uncontrolled hypertension. Points 
for intervention include frequent checks on drug 
adherence, considering its role in causation of resistant 
hypertension, and review of drug regimens.3 Where 
possible, once daily dosing should be used, along 
with fixed dose combination preparations to help 
improve adherence.41 42 Self management and shared 
management between general practitioners and other 
health professionals such as nurses and pharmacists 
can also help improve blood pressure control.43 44 
Educational interventions targeted at patients may help 
to improve awareness and encourage adherence.45 Our 
RESEARCH
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results are generalisable within the UK and also bear 
similarities to estimates from various other countries. 
However, differences in the organisation of care and 
the implementation of policy initiatives likely lead to a 
unique pattern of trends in the UK.
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